Sean Lawless, MD
Cardiovascular Disease · Orem, UTNPI 1720475122
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,172 of the $8,252 with a category attached, or 86.9%. 36 manufacturers reported payments, led by Abbott at 25.7% of the total.
Across 338 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$897
- Amgen$857
- Pfizer$848
- Boehringer Ingelheim$473
- Novartis$467
- plus $3K from 30 others
What the payments were for
- Travel & lodging$1,05413%
- Food & beverage$7,17287%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $2,120 |
| E.r. Squibb & Sons, L.L.C. | 43 | $897 |
| Amgen | 41 | $857 |
| Pfizer | 60 | $848 |
| Boehringer Ingelheim | 29 | $473 |
| Novartis | 24 | $467 |
| Merck | 26 | $437 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $372 |
| Johnson & Johnson | 18 | $267 |
| Bayer | 14 | $227 |
| AstraZeneca | 5 | $179 |
| Novo Nordisk | 2 | $142 |
| Vifor Pharma, Inc. | 1 | $117 |
| Boston Scientific | 7 | $107 |
| Actelion Pharmaceuticals US, Inc. | 7 | $103 |
| Alnylam Pharmaceuticals Inc. | 3 | $74 |
| Daiichi Sankyo Inc. | 4 | $72 |
| Astellas Pharma US Inc | 3 | $69 |
| Acacia Pharma Inc | 2 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Philips North America LLC | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Endotronix, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| CMP Pharma, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Heartflow, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Abiomed | 1 | $14 |
| Analog Devices Inc. | 1 | $14 |
| Biotronik Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$1,274
- CardioMEMS HF System$645
- CAMZYOS$242
- FARXIGA$124
- Wegovy$122
- Repatha$120
- Veltassa$117
How this compares
$8,252 in reported general payments places this provider in the 75th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 350 | $392,394 |
| FarxigaDapagliflozin Propanediol | 321 | $294,387 |
| JardianceEmpagliflozin | 125 | $124,180 |
| CamzyosMavacamten | 12 | $100,270 |
| EntrestoSacubitril/Valsartan | 104 | $93,859 |
| XareltoRivaroxaban | 62 | $75,396 |
| Repatha SureclickEvolocumab | 24 | $17,641 |
| BrilintaTicagrelor | 15 | $16,173 |
| Metoprolol Succinate | 528 | $8,063 |
| Rosuvastatin Calcium | 426 | $6,811 |
| Atorvastatin Calcium | 323 | $4,240 |
| ClopidogrelClopidogrel Bisulfate | 254 | $3,649 |
| Amiodarone Hcl | 154 | $3,375 |
| Prasugrel Hcl | 36 | $2,770 |
| Amlodipine Besylate | 243 | $1,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $848 | $392,394350 claims |
| AstraZenecaFarxiga, Brilinta | $179 | $310,560336 claims |
| Boehringer IngelheimJardiance | $473 | $124,180125 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $897 | $100,27012 claims |
| NovartisEntresto | $467 | $93,859104 claims |
| Johnson & JohnsonXarelto | $267 | $75,39662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Orem
- Charles DahlOrem$39K
- Ronald AsayOrem$8K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.